Detalles de la búsqueda
1.
Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters.
Xenobiotica
; 51(6): 668-679, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33879032
2.
Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Drug Metab Dispos
; 48(3): 217-229, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31911485
3.
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
Drug Metab Dispos
; 45(10): 1049-1059, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28646080
4.
Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Drug Metab Dispos
; 43(4): 620-30, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25655830
5.
Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene.
Carcinogenesis
; 34(9): 2184-91, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23671133
6.
Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor.
Clin Pharmacol Drug Dev
; 11(2): 142-149, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34989180
7.
Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT4 Receptor Agonist.
Eur J Drug Metab Pharmacokinet
; 47(3): 371-386, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35157234
8.
A refined cytochrome P540 IC50 shift assay for reliably identifying CYP3A time-dependent inhibitors.
Drug Metab Dispos
; 39(6): 1054-7, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21393461
9.
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
J Pharmacol Exp Ther
; 332(2): 562-8, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19889796
10.
Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.
Drug Metab Dispos
; 38(9): 1612-22, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20516252
11.
Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.
Drug Metab Dispos
; 36(7): 1261-6, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18381488
12.
Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Drug Metab Dispos
; 36(7): 1255-60, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18381489
13.
CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.
Eur J Drug Metab Pharmacokinet
; 43(3): 347-354, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29264831
14.
Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans.
Drug Metab Lett
; 10(1): 22-37, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26031460
15.
Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.
Curr Top Med Chem
; 5(11): 1033-8, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16181128
16.
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.
ACS Med Chem Lett
; 6(6): 630-4, 2015 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26101564
17.
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Drug Metab Lett
; 7(2): 96-104, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24484538
18.
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Cancer Chemother Pharmacol
; 72(6): 1255-64, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101146
19.